VICP — Vicapsys Life Sciences Income Statement
0.000.00%
Last trade - 00:00
- $31.11m
- $31.36m
- 12
- 56
- 17
- 18
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 1.03 | 0.766 | 0.337 | 0.985 |
Operating Profit | -1.03 | -0.766 | -0.337 | -0.985 |
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -1.03 | -0.766 | -0.237 | -0.985 |
Provision for Income Taxes | ||||
Net Income After Taxes | -1.03 | -0.766 | -0.237 | -0.985 |
Net Income Before Extraordinary Items | ||||
Extraordinary Items | ||||
Net Income | -1.41 | -0.766 | -0.237 | -0.985 |
Adjustments to Net Income | ||||
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -1.57 | -0.766 | -0.237 | -0.988 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.105 | -0.044 | -0.013 | -0.021 |